In Brief: Cardiovascular Diagnostics/Bayer
This article was originally published in The Gray Sheet
Executive Summary
Cardiovascular Diagnostics/Bayer: Reach deal under which Cardiovascular Diagnostics (CVD) will develop a diagnostic point-of-care test for monitoring antithrombin (AT), a regulatory protein that helps control clotting activity in the body. Bayer produces Thrombate III, a concentrate of AT made from blood, which currently is approved for treating AT congenital deficiency. Under terms of the deal, CVD will obtain access to Bayer clinical trial data for Thrombate III for use in a future 510(k) submission. Bayer will have the first right of refusal to co-market Thrombate III with the POC test upon FDA clearance, "which could come sometime in 1997," CVD predicts...
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.